Yoshihito Shima

8.1k total citations · 1 hit paper
78 papers, 5.1k citations indexed

About

Yoshihito Shima is a scholar working on Immunology, Rheumatology and Pathology and Forensic Medicine. According to data from OpenAlex, Yoshihito Shima has authored 78 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Immunology, 22 papers in Rheumatology and 21 papers in Pathology and Forensic Medicine. Recurrent topics in Yoshihito Shima's work include Systemic Lupus Erythematosus Research (15 papers), Systemic Sclerosis and Related Diseases (15 papers) and Multiple Myeloma Research and Treatments (11 papers). Yoshihito Shima is often cited by papers focused on Systemic Lupus Erythematosus Research (15 papers), Systemic Sclerosis and Related Diseases (15 papers) and Multiple Myeloma Research and Treatments (11 papers). Yoshihito Shima collaborates with scholars based in Japan, United States and Canada. Yoshihito Shima's co-authors include Teru Hideshima, Kenneth C. Anderson, Paul G. Richardson, Dharminder Chauhan, Steven P. Treon, Toshio Tanaka, Tôru Hirano, Atsushi Ogata, Tadamitsu Kishimoto and Faith E. Davies and has published in prestigious journals such as Blood, PLoS ONE and Biochemical and Biophysical Research Communications.

In The Last Decade

Yoshihito Shima

73 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

2000 708 citations Teru Hideshima, Dharminder Chauhan et al. profile →

Peers

Countries citing papers authored by Yoshihito Shima

Since Specialization

Citations

This map shows the geographic impact of Yoshihito Shima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshihito Shima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshihito Shima more than expected).

Fields of papers citing papers by Yoshihito Shima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshihito Shima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshihito Shima. The network helps show where Yoshihito Shima may publish in the future.

Co-authorship network of co-authors of Yoshihito Shima

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshihito Shima. A scholar is included among the top collaborators of Yoshihito Shima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshihito Shima. Yoshihito Shima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Factors Influencing Treatment Satisfaction and Recognition Gaps Between Physicians and Patients with Systemic Sclerosis 2025 ·Rheumatology and Therapy ·Yoshihito Shima, (unknown), Sei‐ichiro Motegi, Tsutomu Shimada, Hitoshi Ishii, Yukihiro Ohya, Yasumasa Kanai	0
2	Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial 2023 ·Modern Rheumatology ·Masataka Kuwana, Kazuhiko Takehara, Yoshiya Tanaka, (unknown), Kyoko S. Katsumata, (unknown), Yoshihito Shima	5
3	Monitoring of Sleep Indicators, Physical Activity, Pain, and Fatigue in Patients with Systemic Lupus Erythematosus and Relations among These Variables: A Pilot Study 2023 ·Open Journal of Nursing ·(unknown), Kazuko Shiozawa, (unknown), Yoshihito Shima, Tôru Hirano, Kiyoko Makimoto	0
4	Heating of the neck or elbows alleviates Raynaud’s phenomenon but has different effects on different types of patients with systemic sclerosis 2023 ·Modern Rheumatology ·Yoshihito Shima, A. Watanabe, (unknown), (unknown), Eiji Kunitomo, Atsushi Kumanogoh	0
5	The proliferative activity levels of each immune cell population evaluated by mass cytometry are linked to the clinical phenotypes of systemic lupus erythematosus 2022 ·International Immunology ·(unknown), Takayoshi Morita, Yasuhiro Kato, (unknown), Teruaki Murakami, Yuta Yamaguchi, Shohei Koyama, Hyota Takamatsu, Masayuki Nishide, Yuichi Maeda, A. Watanabe, (unknown), Tôru Hirano, Yoshihito Shima, Masashi Narazaki, Atsushi Kumanogoh	9
6	Predictors of poor sleep quality in patients with systemic lupus erythematosus 2017 ·Clinical Rheumatology ·(unknown), Kazuko Shiozawa, Ryouhei Yoshihara, Takashi Yamane, Yoshihito Shima, Tôru Hirano, Kiyoko Makimoto	27
7	The Proportion of Regulatory T Cells in Patients with Rheumatoid Arthritis: A Meta-Analysis 2016 ·PLoS ONE ·Takayoshi Morita, Yoshihito Shima, James B. Wing, Shimon Sakaguchi, Atsushi Ogata, Atsushi Kumanogoh	78
8	Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab 2011 ·Modern Rheumatology ·Sumiyuki Nishida, Tomio Kawasaki, Hirokazu Kashiwagi, (unknown), (unknown), Mari Kawai, Tôru Hirano, Taeko Ishii, Keisuke Hagihara, Yoshihito Shima, Masashi Narazaki, Atsushi Ogata, Yoshitaka Oka, Tadamitsu Kishimoto, Toshio Tanaka	14
9	A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab 2011 ·Modern Rheumatology ·Tôru Hirano, Nobuyuki Ohguro, (unknown), Keisuke Hagihara, Yoshihito Shima, Masashi Narazaki, Atsushi Ogata, Kazuyuki Yoshizaki, Atsushi Kumanogoh, Tadamitsu Kishimoto, Toshio Tanaka	87
10	Blockade of Interleukin-6 Receptor Alleviates Disease in Mouse Model of Scleroderma 2011 ·American Journal Of Pathology ·Shun Kitaba, Hiroyuki Murota, Mika Terao, Hiroaki Azukizawa, Fumitaka Terabe, Yoshihito Shima, Minoru Fujimoto, Toshio Tanaka, Tetsuji Naka, Tadamitsu Kishimoto, Ichiro Katayama	97
11	Effect of Enzymatically Modified Isoquercitrin, a Flavonoid, on Symptoms of Japanese Cedar Pollinosis: A Randomized Double-Blind Placebo-Controlled Trial 2009 ·International Archives of Allergy and Immunology ·Mari Kawai, Tôru Hirano, Junsuke Arimitsu, Shinji Higa, Yusuke Kuwahara, Keisuke Hagihara, Yoshihito Shima, Masashi Narazaki, Atsushi Ogata, Mihoko Koyanagi, (unknown), Ryosuke Shimizu, Masamitsu Moriwaki, Yukio Suzuki, Satoshi Ogino, Ichiro Kawase, Toshio Tanaka	36
12	Quantification of hardness, elasticity and viscosity of the skin of patients with systemic sclerosis using a novel sensing device (Vesmeter): a proposal for a new outcome measurement procedure 2008 ·Lara D. Veeken ·Yusuke Kuwahara, Yoshihito Shima, (unknown), Masao Kawai, Keisuke Hagihara, Tôru Hirano, Junsuke Arimitsu, Atsushi Ogata, Toshio Tanaka, Ichiro Kawase	48
13	Proteomics‐based identification of α‐enolase as a tumor antigen in non‐small lung cancer 2007 ·Cancer Science ·Ping He, Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Toshio Tanaka, Shoji Hashimoto, Yoshihito Shima, Tomoki Yamadori, Hidekazu Suzuki, Tomonori Hirashima, Kaoru Matsui, Hiroyuki Shiono, Meinoshin Okumura, Toshiro Nishida, Isao Tachibana, Naoko Norioka, Shigemi Norioka, Ichiro Kawase	95
14	Flavonoids and Related Compounds as Anti-Allergic Substances 2007 ·Allergology International ·Mari Kawai, Tôru Hirano, Shinji Higa, Junsuke Arimitsu, (unknown), Yusuke Kuwahara, Tomoharu Ohkawara, Keisuke Hagihara, Tomoki Yamadori, Yoshihito Shima, Atsushi Ogata, Ichiro Kawase, Toshio Tanaka	285
15	IL-18 gene polymorphisms affect IL-18 production capability by monocytes 2006 ·Biochemical and Biophysical Research Communications ·Junsuke Arimitsu, Tôru Hirano, Shinji Higa, Mari Kawai, Tetsuji Naka, Atsushi Ogata, Yoshihito Shima, Minoru Fujimoto, Tomoki Yamadori, Keisuke Hagiwara, (unknown), (unknown), Ichiro Kawase, Toshio Tanaka	92
16	Remission of the Renal Involvement in a Patient with Primary Sjo¨gren’s Syndrome (SS) after Pulse High-Dose Corticosteroid Infusion Therapy 2001 ·Clinical Rheumatology ·Yukihiko Saeki, Satoshi Ohshima, Tomo Ishida, Yoshihito Shima, (unknown), Kiyoshi Nishioka, N. Yamaguchi, Masaki Suemura	15
17	Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications 2001 ·Leukemia ·(unknown), (unknown), Yoshihito Shima, Teru Hideshima, Klaus Podar, (unknown), Boris K. Lin, Suzanne Lentzsch, Faith E. Davies, Dharminder Chauhan, R Schlossman, Paul G. Richardson, P Ralph, Lizi Wu, Faribourz Payvandi, George W. Muller, (unknown), (unknown)	450
18	MYELOMA BIOLOGY AND THERAPY 1997 ·Hematology/Oncology Clinics of North America ·(unknown), Yoshihito Shima, (unknown), (unknown)	14
19	Serum Interleukin 6 as a Predicator of the Therapeutic Effect and Adverse Reactions After Transcatheter Arterial Embolization 1995 ·Cytokine ·Hideya Yamazaki, Norihiro Nishimoto, Hiromichi Oi, Masaki Matsushita, Atsushi Ogata, Yoshihito Shima, Takehiro Inoue, (unknown), (unknown), Tadamitsu Kishimoto, Toshihiko Inoue	4
20	GP130 in Human Myeloma/Plasmacytoma 1995 ·Current topics in microbiology and immunology ·Yoshihiko Tani, Naoki Nishimoto, Atsushi Ogata, Yoshihito Shima, Kazuyuki Yoshizaki, Tadamitsu Kishimoto	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact